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DiseasesPhthalates are widely used as plasticizers to soften and increase the ﬂexibility in polyvinyl chloride plastics,
but they can leach into the surrounding environment. There is sufﬁcient evidence in rodents that phthalate
exposure causes developmental and reproductive toxicity.
The curated interactions between 16 phthalates and genes/proteins were obtained from Comparative
Toxicogenomics Database (CTD), and a total of 445 interactions between the ﬁve most frequently curated
phthalates (DEHP/MEHP and DBP/BBP/MBP) and 249 unique genes/proteins were found. The GeneOntology,
pathways and networks of these 249 unique genes/proteins were fully analyzed. The pathways and networks
of top 34 genes/proteins were found to be very similar to those of the 249 unique genes/proteins. Thus, the top
34 genes/proteins may serve as molecular biomarkers of phthalate toxicity.
The top three phthalate toxicity categories were found to be cardiotoxicity, hepatotoxicity and nephrotoxicity,
and the top 20 diseases included cardiovascular, liver, urologic, endocrine and genital diseases.Comparative Toxicogenomics
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Table 1
Curated interactions
Phthalates
DEHP/MEHPa
DBP/BBP/MBPb
Phthalic acid
Di-n-pentyl phtha
Dicyclohexyl phth
Diallyl phthalate
Diethyl phthalate
Diisodecyl phthala
Di-n-hexyl phthal
Diisobutyl phthala
Di-n-octyl phthala
Diisononyl phthala
Diheptyl phthalate
16 phthalates
aDEHP, diethylhexyl
MEHP, mono-(2-eth
bDBP, dibutyl phthal
BBP, butylbenzyl ph
MBP, monobutyl pht
c(256+189)/539=
l rights reserved.© 2010 Elsevier Inc. All rights reserved.between 16 phthalates and genes/proteins.
Phthalate–gene interactions
256c
189c
17
late 15
alate 12
10
10
te 7
ate 6
te 6
te 5
te 4
21. Introduction
Phthalates are a group of similar diesters of phthalic acid used as
plasticizers to soften and increase the ﬂexibility in polyvinyl chloride
(PVC) plastics. Since phthalates are not covalently bound to plastics,
they can leach into the surrounding environment [1,2]. Human
exposure to phthalates mainly occurs through foods, because of the
use of PVC in wrapping materials and food processing [3]. Phthalates
are also found inmeat, ﬁsh, milk products, and other foods with a high
fat content. Diethylhexyl phthalate (DEHP) is produced by reacting 2-
ethylhexanol with phthalic anhydride, and it is the highest production
volume chemical. When ingested through food contamination, DEHP
is converted by intestinal lipases to mono-(2-ethylhexyl) phthalate
(MEHP), which is then preferentially absorbed. DEHP is currently the
only phthalate plasticizer used in PVC medical devices such as
intravenous tubing and blood transfusion bags [4]. Other sources of
DEHP are indoor air and work exposure in manufacturing factories.Sum 539c
phthalate 157
ylhexyl)phthalate 99
ate 150
thalate 33
halate 6
445/539=83%.
Fig. 1. Venn diagram of phthalate-interacting genes/proteins. DEHP/MEHP and DBP/
BBP/MBP were found to interact with 183 and 112 unique genes/proteins, and 46 of
them were in common. Thus, there were 249 unique genes/protein.
149S. Singh, S.S.-L. Li / Genomics 97 (2011) 148–157Dibutyl phthalate (DBP) is produced by reacting n-butanol with
phthalic anhydride. Unlikemany phthalates, DBP is not currently used
as a plasticizer in PVC plastics. Typically, DBP is used as a component
of latex adhesives. It is also used in cosmetics and other personal care
products, as a plasticizer in cellulose plastics, and as a solvent for dyes
[5]. Monobutyl phthalate (MBP) is the embryotoxic metabolite of
butylbenzyl phthalate (BBP) and DBP.
Environmental chemicals have been shown to play a critical role in
the etiology of many human diseases. The impact of phthalate
exposure on human health has been extensively reviewed and
reported by the National Toxicology Program—Center for theTable 2
34 most frequently curated phthalate-interacting genes/proteins.
Gene symbols DEHP/MEHP DBP/BBP/MBP Sum Human Rat Mouse Others G
PPARA 15 1 16 5 4 6 1 P
PPARG 9 1 10 3 5 1 1 P
PPARD 5 1 6 2 4 – – P
NR1I2 5 4 9 4 2 – 3 N
STAR 4 8 12 – 6 2 4 S
HSD3B1 4 2 6 – 3 3 – H
INSL3 3 6 9 – 6 – 3 I
NR0B1 3 3 6 – 6 – – N
ESR1 2 11 13 9 – – 4 E
CYP11A1 2 7 9 1 4 – 4 C
CYP17A1 2 5 7 – 4 – 3 C
CYP1B1 2 2 4 4 – – – C
CYP4A1 2 2 4 – 3 1 – C
TSPO 2 2 4 – 4 – – T
EGR1 2 1 3 – 3 – – E
MYC 2 1 3 1 1 1 – V
SCARB1 1 5 6 – 3 – 3 S
VEGFA 1 5 6 6 – – – V
ESR2 1 4 5 4 – – 1 E
GRB14 1 3 4 – 4 – – G
LHCGR 1 3 4 – 3 – 1 L
AHR 1 2 3 – – 3 – A
HNF1A 1 2 3 – 3 – – H
INSIG1 1 2 3 – 3 – – I
LDLR 1 2 3 – 3 – – L
SVS5 1 2 3 – 3 – – S
FABP3 4 – 4 – 4 – – F
SLC27A1 4 – 4 – 4 – – S
CELSR2 3 – 3 1 – 2 – C
CYP19A1 3 – 3 – 3 – – C
MT1 3 – 3 – – 3 – M
MT2 3 – 3 – – 3 – M
AR – 9 9 3 3 1 2 A
SLC5A5 – 3 3 2 1 – – S
34 SUM 94 99 193 45 92 26 30
249 SUM 256 189 445 55 301 40 49Evaluation of Risks to Human Reproduction [6]. There is sufﬁcient
evidence in rodents, but not yet in humans, that phthalate exposure
causes developmental and reproductive toxicity. The Comparative
Toxicogenomics Database (CTD; http://ctd.mdibl.org) has been
established to analyze the impact of environmental chemicals on
human health [7]. Biocurators at CTD manually curate toxicogenomic
data, including over 116,000 interactions between 3900 chemicals
and 13,300 genes/proteins from 270 species, 5900 gene/protein–
disease direct relationships, and 2500 chemical–disease direct
relationships. In order to understand the potential adverse health
effects of the most abundantly used DEHP/MEHP and DBP/BBP/MBP,
the curated interactions between these ﬁve phthalates and genes/
proteins were downloaded from CTD, and 249 phthalate-interacting
genes/proteins were fully analyzed for their GeneOntology (GO),
pathways, networks, and human diseases inferred by the phthalate–
gene/protein–disease relationships in this investigation.2. Material and methods
2.1. Curated interaction analysis
All curated interactions of phthalate–genes/proteins, phthalate–
diseases, and gene/protein–diseases in CTD are publicly available [7],
and this analysis reported here was based on data downloaded on July
2, 2009. Prior to analysis, the data set was ﬁrst manually processed:
(1) all curated interactions with phthalates were ﬁrst summarized
and then only the interactions with DEHP/MEHP and DBP/BBP/MBP
were analyzed in details, (2) “no effect” interactions were removed,
and (3) binary interactions were identiﬁed [8].ene names
eroxisome proliferator-activated receptor alpha
eroxisome proliferator-activated receptor gamma
eroxisome proliferator-activated receptor delta
uclear receptor subfamily 1, group I, member 2
teroidogenic acute regulatory protein
ydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1
nsulin-like 3 (Leydig cell)
uclear receptor subfamily 0, group B, member 1
strogen receptor 1
ytochrome P450, family 11, subfamily A, polypeptide 1
ytochrome P450, family 17, subfamily A, polypeptide 1
ytochrome P450, family 1, subfamily B, polypeptide 1
ytochrome P450, family 4, subfamily a, polypeptide 1
ranslocator protein (18 kDa)
arly growth response 1
-myc myelocytomatosis viral oncogene homolog (avian)
cavenger receptor class B, member 1
ascular endothelial growth factor A
strogen receptor 2 (ER beta)
rowth factor receptor-bound protein 14
uteinizing hormone/choriogonadotropin receptor
ryl hydrocarbon receptor
NF1 homeobox A
nsulin induced gene 1
ow density lipoprotein receptor
eminal vesicle secretory protein 5
atty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)
olute carrier family 27 (fatty acid transporter), member 1
adherin, EGF LAG seven-pass G-type receptor 2 (ﬂamingo homolog, Drosophila)
ytochrome P450, family 19, subfamily A, polypeptide 1
etallothionein 1
etallothionein 2
ndrogen receptor
olute carrier family 5 (sodium iodide symporter), member 5
Table 3
Top 20 GO molecular functions analyzed by MetaCore and Pathway Studio.
GO molecular functions p-value
MetaCore Pathway Studio
G-protein coupled receptor activity 3.61E−28 1.49E−20
Receptor activity 2.25E−23 1.71E−23
Signal transducer activity 4.48E−19 2.31E−20
Cadmium ion binding 2.46E−14 3.64E−17
Steroid hormone receptor activity 8.76E−14 2.87E−10
Ligand-dependent nuclear receptor activity 1.39E−11 3.33E−14
Transmembrane receptor activity 5.08E−21
Molecular transducer activity 4.48E−19
Peptide receptor activity 1.23E−18
Peptide binding 4.12E−18
Peptide receptor activity, G-protein coupled 5.18E−17
Neurotransmitter binding 1.50E−13
Neurotransmitter receptor activity 4.41E−13
Icosanoid receptor activity 1.10E−12
Prostanoid receptor activity 1.10E−12
Hormone binding 1.60E−12
Neuropeptide receptor activity 6.76E−12
Neuropeptide binding 8.67E−12
Prostaglandin receptor activity 4.78E−11
Amine receptor activity 1.34E−10
Rhodopsin-like receptor activity 1.71E−42
Adrenoceptor activity 1.26E−09
Protein binding 2.54E−09
Neuropeptide Y receptor activity 2.66E−09
Monooxygenase activity 3.46E−09
Metabotropic glutamate,
GABA-B-like receptor activity
7.27E−09
Sequence-speciﬁc DNA binding 1.33E−08
Copper ion binding 1.55E−08
Tachykinin receptor activity 1.84E−08
Protein heterodimerization activity 2.07E−08
Transcription factor activity 5.59E−08
Xenobiotic-transporting ATPase activity 9.14E−08
Transcription activator activity 1.20E−07
Double-stranded DNA binding 1.59E−07
150 S. Singh, S.S.-L. Li / Genomics 97 (2011) 148–1572.2. GeneOntology, pathway and network analyses
GeneOntology (GO), pathways and networks of phthalate-inter-
acting genes/proteins were analyzed using the software programs
from MetaCore Analytical Suite (GeneGO, Inc.), Ingenuity Pathways
Analysis (IPA, Ingenuity Systems), and/or Pathway Studio (Ariadne,
Inc.). The MetaCore can analyze GO molecular functions and GeneGo
maps (pathways). The Pathway Studio is better to analyze pathways
and networks among chemicals, genes/proteins and diseases in
addition to GO molecular functions. The IPA is best suitable for
analysis of Tox Functions besides pathways and networks.
2.3. Disease analysis
There are two sources for direct disease relationship in CTD:
curation of chemical–disease and gene/protein–disease relationships
from the literature, and integration of gene–disease relationships
from the Online Mendelian Inheritance in Man (OMIM; http://www.
ncbi.nlm.nih.gov/omim) database. The potential human diseases
inferred by the phthalate–gene/protein–disease relationships from
CTD and OMIM were analyzed using IPA Tox Functions.
3. Results
3.1. Phthalate–gene/protein interactions
A total of 539 phthalate–gene/protein interactions (excluding no
effects) were found for 16 phthalates from the CTD as of July 2, 2009.
Since DEHP is in vivo metabolized quantitatively to its monoester
MEHP, the DEHP and MEHP were thus combined as a group. Likewise,
DBP, BBP and MBP were pooled together, because MBP is the
embryotoxic metabolite of DBP and BBP. The ﬁve most frequently
curated chemicals DEHP/MEHP and DBP/BBP/MBP exhibited 256 and
189 interactions, respectively, and their sum of 445 interactions
accounted for 83% of all 539 interactions (Table 1). Only DEHP/MEHP
and DBP/BBP/MBP groups were further analyzed in details. DEHP/
MEHP and DBP/BBP/MBP interacted with 183 and 112 unique genes/
proteins, respectively, and 46 of them were in common (Fig. 1). Thus,
there were 249 unique genes/proteins exhibiting a total of 445
interactions with DEHP/MEHP and DBP/BBP/MBP (Supplementary
Table S1), and the top 34 unique genes/proteins with three and more
interactions are summarized in Table 2. It is of interest that DEHP/
MEHP was found to have at least ﬁve interactions with all three PPAR
isotypes (PPARA, PPARG and PPARD), while DBP/BBP/MBP had only
one interaction with each of these three genes/proteins. DBP/BBP/
MBP was found to have eleven and nine interactions with ESR1 and
AR, but DEHP/MEHP had only two and none, respectively. It may also
be noted that ESR1 and VEGFA genes/proteins had nine and six
interactions, respectively, with DEHP/MEHP and DBP/BBP/MBP in
humans, but none in rodents.
3.2. GeneOntology, pathway and network analyses
The GO molecular functions of 249 unique phthalate-interacting
genes/proteins were analyzed by both MetaCore and Pathway Studio,
and their top 20 functions are listed in Table 3. 13 and 10 out of their
top 20 functions obtained by MetaCore and Pathway Studio,
respectively, were involved with different receptor activities, and
six of their top 20 functions identiﬁed by both methods were further
found to be in common. It should be noted that many of the GeneGo
pathways and GeneGo process networks of 249 unique phthalate-
interacting genes/proteins were found to be very similar to those of
the top 34 unique genes/proteins with three and more curated
phthalate interactions (Fig. 2), suggesting that this subset of 34
unique genes/proteins may represent the overall biology of 249
genes/proteins responding to phthalate exposure. It is of interest thatthe top four pathways were involved in the regulation of lipid
metabolism, and PPAR pathway. It may be further noted that three
PPARs complexing with retinoid X receptor (RXRA) played important
roles in many normal and pathological biological processes such as
atherosclerosis and hepatocarcinogenesis (Fig. 3).
3.3. Toxicity and disease associations
The toxicity of 249 unique genes/proteins interacting with DEHP/
MEHP and DBP/BBP/MBP was analyzed using IPA Tox Functions, and
their top three categories were cardiotoxicity, hepatotoxicity and
nephrotoxicity (Table 4). The pathways and networks of the top three
toxicities of MEHP and DBP were further analyzed by Pathway Studio
(Fig. 4). The curated interactions of DEHP/MEHP and DBP/BBP/MBP
with 249 unique genes/proteins in CTD have inferred relationships
with 1437 GeneGo diseases identiﬁed using MetaCore by biomarkers,
and the top 20 diseases are listed in Table 5. The top 20 diseases
included cardiovascular diseases, liver diseases, urologic diseases,
endocrine diseases, and genital diseases in addition to the number 1
disease-disorder of environmental origin.
4. Discussion
In this investigation, the ﬂow chart for the different steps of our
analyses is shown in Fig. 5. DEHP/MEHP, as well as DBP/BBP/MBP, was
found to interact with all three PPAR isotypes PPARA, PPARD and
PPARG (Table 2), and these three PPARs were reported to be
functionally activated by DEHP/MEHP [9]. PPARs play broad roles in
lipid and carbohydrate metabolism (Fig. 3), and they are involved in
metabolic disorders such as atherosclerosis, hyperlipidemia, and
Fig. 2. Comparison of GeneGo pathway maps and process networks of 249 and top 34 unique genes/proteins. The top 10 GeneGo canonical pathway maps of top 34 genes/proteins
(blue/while strips) and the other 215 genes/proteins (brown band). The degree of “relevance” to different GeneGo ontology categories is deﬁned by p-value, so that the lower
random p-value gets higher priority. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
151S. Singh, S.S.-L. Li / Genomics 97 (2011) 148–157obesity, which in general develop slowly over many years [10]. These
disorders are consistent with the ﬁnding of the cardiotoxicity,
including cardiovascular diseases, among top disorders caused by
phthalate exposure (Table 4). The developmental effects of DBP/BBP/
MBP depend on the embryonic age at the time of exposure and
exposure duration. These effects are mainly on mesodermal struc-
tures, including cardiovascular and urogenital malformation. Recent-
ly, the cardiomyocyte differentiation of murine embryonic stem cells
was reported to be inhibited by MBP [11]. Several urinary phthalate
metabolites were also reported to be associated with key features of
the metabolic syndrome (body mass index, abdominal adiposity and
insulin resistance) [12,13].
Peroxisome proliferation is often seen in the liver and kidney, and
sustained peroxisome proliferation phenomenon can lead to carcino-
genesis. The activation of PPARA, which was the most frequentlycurated gene/protein, was responsible for the DEHP/MEHP toxicity,
especially, liver tumors in rodents [14]. This mechanism may be less
relevant for humans because of lower expression of PPARA in the
human liver compared to that seen in the rodent liver. However,
PPARA-deﬁcient mice did develop hepatocarcinogenesis under DEHP
exposure [15], and this was due to activation of constitutive
androstane receptor [16,17]. DEHP/MEHP was also reported to have
marked nephrotoxic effects on cultured kidney epithelial cells [18].
DEHP/MEHP causes animal toxicity inmany organ systems [19,20].
Studies at low doses of exposure, which appear to be of most concern
for humans, have demonstrated subtle reproductive toxicity in male
rodents [21]. Since fetal and neonatal stages seem to be the critical
periods for exposure to DEHP/MEHP, a similar toxicity (for example,
impaired fertility) in humans might be dormant and might not
become manifest for many years, until adulthood is reached. In
152 S. Singh, S.S.-L. Li / Genomics 97 (2011) 148–157humans, population studies have established that dysmorphic
disorders of the genital tract, observed in male infants, are
signiﬁcantly associated with prenatal exposure to phthalates. These
effects likely result from the antiandrogenic and estrogeno-mimetic
activities of DEHP/MEHP [22].
DBP/BBP/MBP, but not DEHP/MEHP, was found to have nine
curated interactions with AR gene/protein (Table 2). However, these
phthalates do not interact directly with the androgen receptor, but
rather disrupt testosterone synthesis in the rat fetal testis [23]. DBP/Fig. 3. PPAR pathway—MetaCore. The 249 unique genes/proteins were used as input for Met
PPARG (gamma) complexed with retinoid X receptor RXRA (alpha) were involved in normalBBP/MBP is known to affect male fertility and cause testicular
atrophy in young adult rodents. DBP/BBP/MBP also has profound and
permanent effects on the male reproductive development if
exposure occurs during the critical periods of sexual differentiation
(i.e. late in the gestation) [24]. The phenotypic alterations observed
in male offspring rats exposed during the perinatal period have
remarkable similarities with common human reproductive disor-
ders, including cryptorchidism, hypospadias and low sperm counts
[25].aCore pathway analysis. A. Three PPAR isotypes PPARA (alpha), PPARD (delta/beta) and
and pathological processes. B. The explanation of the symbols used in GeneGo pathway.
Fig. 3 (continued).
Table 4
Top three toxicity categories analyzed by IPA Tox Functions.
Name p-value # Molecules
Cardiotoxicity
Heart failure 8.16E−14 to 2.06E−04 21
Tachycardia 1.32E−12 to 1.72E−07 13
Cardiac infarction 1.48E−08 to 2.40E−04 12
Cardiac congestive cardiac failure 4.20E−08 to 4.20E−08 10
Cardiac arrhythmia 5.64E−08 to 1.78E−07 9
Hepatotoxicity
Liver necrosis/cell death 3.54E−09 to 5.89E−02 14
Liver steatosis 1.28E−07 to 4.67E−02 9
Liver hepatomegaly 3.35E−07 to 1.58E−02 6
Liver hepatitis 4.51E−07 to 1.06E−01 9
Liver hyperplasia/hyperproliferation 6.86E−07 to 6.18E−02 6
Nephrotoxicity
Kidney failure 3.31E−10 to 3.14E−02 13
Renal nephritis 6.14E−05 to 2.00E−01 9
Renal proliferation 1.15E−04 to 3.14E−02 5
Renal hydronephrosis 2.42E−04 to 2.00E−02 4
Renal necrosis/cell death 3.52E−04 to 1.46E−03 5
153S. Singh, S.S.-L. Li / Genomics 97 (2011) 148–157The widespread exposure of the general human population has
been demonstrated in several recent biomonitoring studies in the USA
and Europe [2,26,27]. The potential public health risks associated with
phthalate exposure include not only metabolic disorders, carcinogen-
esis, and reproductive toxicity but also endocrine disruption [28–30].
Estrogen receptor 1 (ESR1) was found to interact with both DEHP/
MEHP and DBP/BBP/MBP in humans, but not in rodents (Table 2). The
widely used phthalates are known to interfere with endocrine
systems, including the estrogen and thyroid hormones [31–33].
Endocrine diseases and thyroid diseases were among the top 20
inferred diseases (Table 5) in this investigation. The vascular
endothelial growth factor A (VEGFA) was also found to interact with
DEHP/MEHP and DBP/BBP/MBP in humans, but not in rodents. DEHP
has recently shown to exert a species-speciﬁc metabolic consequence
of PPARA activation [34].
The pathways and networks of top 34 genes/proteins were found
to be very similar to those of 249 unique genes/proteins interacting
with phthalates DEHP/MEHP and DBP/BBP/MBP. Thus, these top 34
genes/proteins may serve as molecular biomarkers for assaying the
154 S. Singh, S.S.-L. Li / Genomics 97 (2011) 148–157
Fig. 4. The pathways and networks of top three toxicities of MEHP and DBP analyzed by Pathway Studio. The 249 unique genes/proteins were used as input for pathway and network
analyses by Pathway Studio. A, cardiotoxicities; B, heptotoxicites; and C, nephrotoxicities.
155S. Singh, S.S.-L. Li / Genomics 97 (2011) 148–157toxicity of phthalates. Advances in the measurement of molecular
biomarkers hold much promise in facilitating the study design and
improving the epidemiological data. In view of limited human
experimental evidence, human embryonic stem cells may be
developed using systems biology with the top 34 genes/proteins as
molecular biomarkers to assay the adverse health effects of phthalate
toxicity [35,36]. Human embryonic stem cells may also be differen-
tiated into beating cardiomyocytes as a new tool for testing
cardiotoxicity [37]. Gene expression proﬁles of these differentiated
cardiomyocytes have been found to be reminiscent of developing
contractile cells in the normal human heart.Table 5
Top 20 GeneGo diseases (by Biomarkers).
# Disease name p-value Network objects
1 Disorders of environmental origin 2.755E−34 144/1567
2 Cardiovascular diseases 5.884E−32 153/1833
3 Endocrine system diseases 4.198E−30 161/2080
4 Urologic diseases 5.400E−28 116/1210
5 Vascular diseases 7.040E−28 134/1572
6 Adenocarcinoma 8.261E−27 141/1760
7 Endocrine gland neoplasms 2.822E−26 121/1362
8 Liver diseases 5.730E−26 128/1515
9 Wounds and injuries 1.019E−25 97/928
10 Body weight 2.299E−25 70/504
11 Liver neoplasms 1.708E−24 103/1072
12 Urologic and male genital diseases 8.423E−24 170/2571
13 Autoimmune diseases 2.106E−23 111/1261
14 Pathological conditions 3.817E−23 216/3867
15 Mental disorders 4.066E−23 127/1601
16 Urogenital diseases 4.328E−23 151/2142
17 Prostatic diseases 5.636E−23 110/1256
18 Genital diseases, male 6.712E−23 119/1441
19 Urogenital neoplasms 6.728E−23 147/2057
20 Endometrial neoplasms 1.236E−22 53/3226. Conclusions
A total of 445 interactions curated in CTD were obtained between
the ﬁve most frequently curated phthalates (DEHP/MEHP and DBP/
BBP/MBP) and 249 unique genes/proteins. The pathways and net-
works of the top 34 genes/proteins were found to be very similar to
those of the 249 unique genes/proteins. Thus, the top 34 genes/
proteins may serve as molecular biomarkers of phthalate toxicity. The
top three phthalate toxicity categories were found to be cardiotoxi-
city, hepatotoxicity and nephrotoxicity. Further studies are warranted
to demonstrate the signiﬁcance of these associations of phthalates
with respect to the newly discovered cardio and reno toxicities. The
1437 potential human diseases were inferred by the phthalate–gene/
protein–disease relationships, and the top 20 diseases included
cardiovascular diseases, liver diseases, urologic diseases, endocrine
diseases, and genital diseases in addition to the number 1 disease-
disorder of environmental origin.7. Note added at revision
New CTD data dated September 8, 2010 were similarly analyzed,
and the results described in supplementary Tables S2 and S3 are found
to be very similar to those based on July 2, 2009.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ygeno.2010.11.008.Acknowledgments
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Fig. 5. Flow chart of the different steps in our analyses. The curated interactions between 16 phthalates and genes/proteins were obtained from CTD, and a total of 445 interactions
between the ﬁve most frequently curated phthalates and 249 unique genes/proteins were found. The top 34 genes/proteins may serve as molecular biomarkers of phthalate toxicity.
The top three phthalate toxicity categories were found to be cardiotoxicity, hepatotoxicity and nephrotoxicity.
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